CJC-1295 DAC - Dragon Pharma

CJC-1295 known as a long acting GHRH analog and was developed by a company ConjuChem and introduced in 2005. It enhances the body natural production of growth hormone, leading to increased IGF-1 levels, promoting muscle growth and fat loss. Its extended half-life, lasting up to 10 days, reduces the frequency of use. Though initially promising in clinical trials, further development was discontinued after a fatality in a study conducted in 2006, linked to an unrelated adverse event.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about CJC-1295 DAC by Dragon Pharma, consult with your doctor or healthcare professional.